Literature DB >> 22358925

Regulation of cell growth by IRF-1 in BHK-21 cells.

S Kirchhoff1, A Kröger, H Cruz, M Tümmler, F Schaper, M Köster, H Hauser.   

Abstract

Most cell lines that are used for the production of recombinant proteins proliferate spontaneously at a high rate. In many types of cultivation systems these cells still keep growing after having reached the desired cell density. Further proliferation in batch cultures leads to cell death as a consequence of nutrient and oxygen depletion as well as to accumulation of lactate and toxic products. Consequently, in many technical processes, the surplus of cells is removed.We have established cell lines in which proliferation is controlled by a physiological regulator, IRF-1. IRF-1 (Interferon Regulatory Factor 1) is a transcriptional activator and acts as a tumor suppressor. Constitutive overexpression of recombinant IRF-1 leads to inhibition of cell growth. The extent of this growth arrest depends on the intracellular concentration of active IRF-1. To allow IRF-1 expression in various mammalian cells a system for conditional IRF-1 activation has been established. A fusion protein composed of IRF-1 and the hormone binding domain of the human estrogen receptor, was used. This system allows to control gradually the growth of several mammalian cell lines by adjusting the intracellular concentration of active IRF-1 via estradiol in the medium. We have evaluated BHK-21 cells with respect to IRF-1 mediated cell growth inhibition and expression of two secreted proteins. Whereas the productivity of proliferation inhibited cells with respect to constitutively transcribed IgG genes is reduced, productivity of another secreted protein which is controlled by an IRF-1 inducible promoter is strongly enhanced under these conditions.

Entities:  

Year:  1996        PMID: 22358925     DOI: 10.1007/BF00353934

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  25 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1.

Authors:  T Fujita; Y Kimura; M Miyamoto; E L Barsoumian; T Taniguchi
Journal:  Nature       Date:  1989-01-19       Impact factor: 49.962

3.  Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance.

Authors:  J A Vara; A Portela; J Ortín; A Jiménez
Journal:  Nucleic Acids Res       Date:  1986-06-11       Impact factor: 16.971

4.  Identification of mammalian cell clones exhibiting highly regulated expression from inducible promoters.

Authors:  S Kirchhoff; M Köster; M Wirth; F Schaper; M Gossen; H Bujard; H Hauser
Journal:  Trends Genet       Date:  1995-06       Impact factor: 11.639

5.  Expression of recombinant antibody and secreted alkaline phosphatase in mammalian cells. Influence of cell line and culture system upon production kinetics.

Authors:  A J Racher; J L Moreira; P M Alves; M Wirth; U H Weidle; H Hauser; M J Carrondo; J B Griffiths
Journal:  Appl Microbiol Biotechnol       Date:  1994-02       Impact factor: 4.813

6.  A new dominant hybrid selective marker for higher eukaryotic cells.

Authors:  F Colbère-Garapin; F Horodniceanu; P Kourilsky; A C Garapin
Journal:  J Mol Biol       Date:  1981-07-25       Impact factor: 5.469

7.  Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.

Authors:  T Matsuyama; T Kimura; M Kitagawa; K Pfeffer; T Kawakami; N Watanabe; T M Kündig; R Amakawa; K Kishihara; A Wakeham
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

8.  Constitutive expression of an ISGF2/IRF1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection.

Authors:  R Pine
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker.

Authors:  C R Bebbington; G Renner; S Thomson; D King; D Abrams; G T Yarranton
Journal:  Biotechnology (N Y)       Date:  1992-02

10.  Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes.

Authors:  L F Reis; H Harada; J D Wolchok; T Taniguchi; J Vilcek
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

View more
  6 in total

1.  Using cell engineering and omic tools for the improvement of cell culture processes.

Authors:  Darrin Kuystermans; Britta Krampe; Halina Swiderek; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2007-02-24       Impact factor: 2.058

2.  Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture.

Authors:  F Franek; M Strnad; L Havlícek; V Siglerová; I Fismolová; T Eckschlager
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

3.  Manipulation of culture conditions for BHK cell growth inhibition by IRF-1 activation.

Authors:  A V Carvalhal; J L Moreira; H Cruz; P Mueller; H Hauser; M J Carrondo
Journal:  Cytotechnology       Date:  2000-02       Impact factor: 2.058

4.  Modulation of cell cycle progression and of antibody production in mouse hybridomas by a nucleotide analogue.

Authors:  F Franek; A Holý; I Votruba; T Eckschlager
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

Review 5.  Interferon regulatory factor 1 inactivation in human cancer.

Authors:  Khaldoon Alsamman; Omar S El-Masry
Journal:  Biosci Rep       Date:  2018-05-08       Impact factor: 3.840

6.  IκB kinase-ε-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells.

Authors:  Anna Lisa Remoli; Marco Sgarbanti; Edvige Perrotti; Marta Acchioni; Roberto Orsatti; Chiara Acchioni; Angela Battistini; Robert Clarke; Giulia Marsili
Journal:  Neoplasia       Date:  2020-08-09       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.